ASH 2018 | Alvocidib plus cytarabine and mitoxantrone in MCL1-dependent R/R AML

Tara Lin

In this interview, Tara Lin, MD, of the University of Kansas Medical Center, Kansas City, KS, discusses the results of the Phase II Zella 201 study (NCT02520011) evaluating the clinical response of alvocidib in combination with cytarabine and mitoxantrone (ACM) in MCL1-dependent, relapsed/refractory acute myeloid leukemia (AML) patients. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Lin discusses the clinical activity, particularly in those refractory to frontline therapy, of alvocidib given prior to cytarabine and mitoxantrone in MCL1-dependent AML.

Share this video